Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

2.

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.

Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC.

AIDS. 2007 Jul 31;21(12):1579-89.

3.

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.

Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS.

AIDS. 2007 Mar 30;21(6):685-92.

PMID:
17413689
4.

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.

Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, Huang LY, Chen MY, Hwang JS, Wang JD, Chuang CY.

QJM. 2007 Feb;100(2):97-105.

PMID:
17277317
5.

Survival of persons with and without HIV infection in Denmark, 1995-2005.

Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N.

Ann Intern Med. 2007 Jan 16;146(2):87-95.

PMID:
17227932
6.

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel..

JAMA. 2006 Aug 16;296(7):827-43.

PMID:
16905788
7.

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR.

Lancet. 2006 Aug 5;368(9534):531-6. Review. No abstract available.

PMID:
16890841
8.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration..

Lancet. 2006 Aug 5;368(9534):451-8. Review.

PMID:
16890831
9.

The survival benefits of AIDS treatment in the United States.

Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA.

J Infect Dis. 2006 Jul 1;194(1):11-9. Epub 2006 Jun 1.

PMID:
16741877
10.

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration.; ART Cohort Collaboration (ART-CC) groups..

Lancet. 2006 Mar 11;367(9513):817-24. Erratum in: Lancet. 2006 Jun 10;367(9526):1902.

PMID:
16530575
11.

Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.

Lloyd-Smith E, Brodkin E, Wood E, Kerr T, Tyndall MW, Montaner JS, Hogg RS.

AIDS. 2006 Feb 14;20(3):445-50.

PMID:
16439879
12.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group..

N Engl J Med. 2006 Jan 19;354(3):251-60.

13.

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR; Triservice AIDS Clinical Consortium..

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200.

PMID:
16394852
14.

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M; Swiss HIV Cohort Study..

Lancet. 2005 Jul 30-Aug 5;366(9483):378-84.

PMID:
16054937
15.

There and back again: the impact of adult HIV prevalence on national life expectancies.

McGuire AL, Barer JM, Montaner JS, Hogg RS.

HIV Med. 2005 Mar;6(2):57-8.

16.

Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features.

Staehelin C, Egloff N, Rickenbach M, Kopp C, Furrer H; Swiss HIV Cohort Study..

AIDS Patient Care STDS. 2004 Nov;18(11):665-75.

PMID:
15635749
17.
18.

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.

May M, Royston P, Egger M, Justice AC, Sterne JA; ART Cohort Collaboration..

Stat Med. 2004 Aug 15;23(15):2375-98.

PMID:
15273954
19.

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team..

Lancet. 2004 Apr 17;363(9417):1253-63.

PMID:
15094269
20.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team..

N Engl J Med. 2003 Dec 11;349(24):2293-303.

Supplemental Content

Support Center